Client News

Posted: December 2, 2016, 9:29 pm
Posted: December 2, 2016, 9:05 pm
Posted: December 2, 2016, 4:59 pm
[GlobeNewswire] - NEW YORK, Dec. 02, 2016-- Stemline Therapeutics, Inc. announced today that SL-401, a novel targeted therapeutic directed to CD123, will be featured in seven presentations, including three oral presentations, ...
Posted: December 2, 2016, 12:30 pm
[Business Wire] - Ignyta, Inc. , a biotechnology company focused on precision medicine in oncology, today announced data examining the combination of entrectinib and trametinib in overcoming resistance to TRK inhibition during a late-breaking oral plenary presentation at the 2016 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.
Posted: December 2, 2016, 9:30 am
[at noodls] - CRANBURY, N.J., Nov. 30, 2016/PRNewswire/ -- Palatin Technologies, Inc. ('Palatin') (NYSE MKT: PTN) today announced that it has commenced an underwritten public offering, subject to market and other conditions, ...
Posted: December 1, 2016, 3:22 pm
[at noodls] - REDWOOD CITY, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces that Bernard J. Kelley has been named Chairman of the Board, effective ...
Posted: December 1, 2016, 3:21 pm
[at noodls] - Company to host conference call at 4:30 pm ET today HAYWARD, Calif.--(BUSINESS WIRE)-- Aradigm Corporation (NASDAQ:ARDM) (the 'Company')today announced top-line results from its two Phase 3 clinical trials ...
Posted: December 1, 2016, 3:21 pm
[at noodls] - CRANBURY, N.J., Dec. 1, 2016/PRNewswire/ -- Palatin Technologies, Inc. ('Palatin') (NYSE MKT: PTN) today announced the pricing of an underwritten public offering of 25,384,616 shares of its common stock ...
Posted: December 1, 2016, 3:21 pm
[GlobeNewswire] - The two studies presented at ASH highlight new data on genomic and immune biomarkers, as well as biological pathways of the aggressive cancer diffuse large B-cell lymphoma, the most common form of B-cell ...
Posted: December 1, 2016, 2:21 pm
[PR Newswire] - The Series J warrants are immediately exercisable at a price of $0.80 per share of common stock and will expire on the fifth anniversary of the date of issuance. Canaccord Genuity is acting as sole book-running manager, Roth Capital Partners is acting as lead manager and Chardan Capital Markets is acting as co-manager for the offering.
Posted: December 1, 2016, 1:20 pm
[Reuters] - Aradigm Corp reported mixed data on its inhaled antibiotic for an incurable rare disease associated with chronic lung infections from two late-stage trials. The company's shares tumbled 21.7 percent to $4.10 in light premarket trading on Thursday. The once-a-day formulation, Pulmaquin, is being tested in patients with non-cystic fibrosis bronchiectasis (non-CF BE) who have chronic lung infections with the bacteria P. aeruginosa.
Posted: December 1, 2016, 12:47 pm